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have been only 5 randomised controlled trials of statins in patients
with prior stroke or TIA (total n = 9224) and the estimate of efﬁcacy
in preventing recurrent stroke is marginal (10.8% statin vs 12.1% con-
trol; odds ratio [OR]: 0.88, 95% CI: 0.77 to 1.00) (Manktelow and
Potter, 2009). In the two trials that recorded the pathological subtype
of stroke outcome events, allocation to statins (simvastatin 40 mg
daily (Heart Protection Study Collaborative Group, 2004) or atorvastatinCholesterol Levels (SPARCL) Investigators, 2006)) was associated withIn this issue of EBioMedicine, Naohisa Hosomi and colleagues report
the eagerly awaited results of the Japan Statin Treatment Against Recur-
rent Stroke (J-STARS) trial (Hosomi et al., in press). A total of 1578
Japanese men and women aged 45 to 80 years with previous non-
cardioembolic ischaemic stroke and total cholesterol concentration be-
tween 4.65 and 6.21mmol/l were randomly assigned to open-label prav-
astatin 10 mg per day or to control (no statin, but non-statin drugs were
allowed) and followed for amean of 4.9 years (Hosomi et al., in press). Al-
location to pravastatinwas associatedwith a reduction inmean total cho-
lesterol concentration by 0.57 mmol/l and low-density lipoprotein (LDL)
cholesterol by 0.55 mmol/l compared to control, but no difference in the
primary endpoint of stroke or TIA (2.56% vs 2.65% per year, adjusted haz-
ard ratio [HR] 0.97, 95% conﬁdence interval [CI]: 0.73 to 1.29) (Hosomi
et al., in press). Allocation to pravastatin was however associated with a
lower incidence of ischaemic stroke due to atherothrombosis compared
to control (0.21% vs 0.64% per year, adjusted HR 0.33, 0.15 to 0.74) with-
out increasing intracranial haemorrhage (0.29% vs 0.31% per year, adjust-
ed HR 1.00, 0.45 to 2.22) or mortality (1.11% vs 0.90% per year, adjusted
HR 1.23, 0.79 to 1.93) (Hosomi et al., in press).
The J-STARS trial provides novel data about the safety and efﬁcacy of
statins in preventing recurrent stroke in Japanese (Hosomi et al., in
press). Although statins have been shown conclusively to reduce the
risk of stroke by one sixth (risk ratio [RR]: 0.85, 95% CI: 0.80–0.89) for
every 1.0 mmol/l reduction in LDL cholesterol in 174,000 participants
enrolled in 27 randomised trials (Cholesterol Treatment Trialists'
(CTT) Collaboration, 2015), it has been uncertain whether these resultsom.2015.08.006
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a signiﬁcant reduction in ischaemic stroke (7.9% statin vs 9.9% control;
OR 0.78, 0.67 to 0.92) but also a signiﬁcant increase in haemorrhagic
stroke (1.9% statin vs 1.1%; OR 1.72, 1.20 to 2.46) (Manktelow and
Potter, 2009). As the incidence of haemorrhagic stroke in Japan is
twice that observed in Western countries (Suzuki and Izumi, 2015),
where previous trials in stroke patients were undertaken (Heart
Protection Study Collaborative Group, 2004; The Stroke Prevention by
Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators,
2006), another uncertainty and concern have been whether statins are
safe in Japanese with a history of prior stroke. The only previous
randomised controlled trial of a statin in Japanesewas theManagement
of Elevated cholesterol in the primary prevention Group of Adult
Japanese (MEGA) trial in 7832 Japanese men and women with hyper-
cholesterolaemia (total cholesterol 5.69–6.98 mmol/l) and no history
of stroke (Nakamura et al., 2006). Pravastatin 10–20 mg daily reduced
the risk of coronary heart disease (primary outcome) by one third (HR
0.67, 95% CI 0.49 to 0.9) compared to control but did not have a signiﬁ-
cant effect on any ﬁrst-ever stroke (2.5% vs 3.0%, HR 0.83, 95% CI: 0.57 to
1.21). There was however, a trend toward a reduction in ischaemic
stroke (1.7% vs 2.2%; HR 0.76, 95% CI: 0.49 to 1.18) and increase in intra-
cranial haemorrhage (0.8% vs 0.7%; HR: 1.8, 0.58 to 2.42)with pravastat-
in compared to control, as observed in the two previous trials of statins
in patients with prior stroke (Heart Protection Study Collaborative
Group, 2004; The Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) Investigators, 2006; Suzuki and Izumi,
2015).
The results of the J-STARS trialwill reassure clinicians about the safe-
ty of pravastatin 10 mg per day in Japanese patients with prior ischae-
mic stroke. However, they raise questions about the efﬁcacy of
pravastatin 10 mg daily in preventing stroke or TIA (HR 0.97, 0.73 tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1009G.J. Hankey / EBioMedicine 2 (2015) 1008–10091.29) and any stroke (2.35% vs 2.47% per year, adjusted HR 0.95, 0.71 to
1.28). The failure to prove the efﬁcacy of pravastatin may have several
explanations. First, the study was underpowered to reliably identify or
exclude a modest but clinically signiﬁcant effect of pravastatin because
it only recruited about half (n = 1578) of the initial target sample size
of 3000 and the outcome event rate was lower than expected. Hence,
the estimates are prone to substantial random error as indicated by
their wide 95% conﬁdence intervals. Second, the dose of pravastatin
(10 mg per day) and degree of reduction in LDL cholesterol compared
to control (0.55 mmol/l) may have been too small to generate a detect-
able treatment effect, given that higher doses of pravastatin (40 mg per
day) and greater reductions in LDL cholesterol (≥1.0mmol/l) have been
associated with efﬁcacy (White et al., 2000; Cholesterol Treatment
Trialists' (CTT) Collaboration, 2010). Third, pravastatin may only be ef-
fective in preventing one aetiological subtype of ischaemic stroke —
atherothrombotic, as suggested by a subgroup analysis of the J-STARS
results (Hosomi et al., in press). However, although this subgroup anal-
ysis was pre-speciﬁed, the results are only hypothesis-generating. It
now behoves researchers to explore the hypothesis that more intense
reductions in LDL-cholesterol by higher doses of statins (and other
lipid-lowering interventions, such as anti-PCSK9 antibodies (Zhang
et al., 2015)) may be safe and effective in preventing recurrent ischae-
mic stroke due to atherothrombosis, and recurrent stroke of any type,
in Japanese patients with recent non-cardioembolic ischaemic stroke
and a wide range of LDL cholesterol concentrations.
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